Structure of compound 27

potent pan-PIM kinase inhibitor

oral PD and efficacy in xenograft model

from SBDD of prior lead

Bioorg. Med. Chem. Lett., Oct. 14, 2020

Sanofi, Waltham/Cambridge, MA

“compound 27” (Sanofi oral in vivo pan-PIM kinase inhibitor)


 this content is exclusive to
Premium members

Upgrade to a Premium Drug Hunter membership to unlock the full content and start reading now.